Research & Development: Page 46
-
PharmaVoice Team/PharmaVoice
Speak Out
At the Forefront of Drug Discovery and Development: Small to Midsize Biotech/Biopharma Companies are the Leaders of Innovation Today, the innovators of drug discovery and development often are found in the smaller, biotech and biopharma companies around the world. According to a report from HBM...
By Peter Benton • April 1, 2017 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
Leading from the top Disruption, our experts say in this month’s cover article, is required for the industry to move forward, particularly in light of multiple industry forces. Bernard Munos, senior fellow at FasterCures, Milken Institute, doesn’t like to use the word disruption, because it scare...
By Taren Grom • March 1, 2017 -
Explore the Trendline➔
Getty Images
TrendlineOncology R&D
Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
Upfront
Bayer Campaign Aims to Make Saving Lives Something Common Bayer Aspirin’s latest campaign, timed to American Heart Month, aims to raise awareness about heart attacks and about the role of aspirin in reducing the risk of complications. The HeroSmith campaign began in February 2017 in Fort Smith, A...
By PharmaVoice Team • March 1, 2017 -
PharmaVoice Team/PharmaVoice
HealthTech
Breakthrough Brain Computer Interface for AR/VR Trend Watch: Patches, baby monitors, BCI, artificial skin, and blockchain move healthcare into the future. Neurable, a developer of brain-computer interface (BCI) technology based on breakthrough neuroscience, has raised a $2 million seed round to b...
By PharmaVoice Team • March 1, 2017 -
PharmaVoice Team/PharmaVoice
Trends in Protocol Development
Clinical protocols are the framework for a clinical trial. They provide the structure for assessing a potential product’s safety and efficacy. But over the past 15 years, protocols have increased in endpoints, procedures, eligibility criteria, number of CRFs, protocol amendments, and investigativ...
By Denise Myshko • March 1, 2017 -
PharmaVoice Team/PharmaVoice
Ebola Research Update
In 2014, an outbreak of Ebola in Guinea, West Africa, became a global health crisis within a few months. As the outbreak spread to other countries in West Africa, the crisis strained the countries’ already limited healthcare resources, and spread fear in the United States, as some international h...
By Denise Myshko • March 1, 2017 -
PharmaVoice Team/PharmaVoice
Speak Out
Calling out Clinical Technology Think about your phone – maybe you are even reading this on it – and you’ll probably have an emotional reaction of some kind. It may or may not be a strong reaction, but odds are there is a certain and specific feeling your phone emotes in you. For something that d...
By Kristopher E. Sarajian • March 1, 2017 -
PharmaVoice Team/PharmaVoice
Upfront
Trends in Biopharma Innovation Over the last 20 years, a total of 667 innovative biopharmaceuticals have launched in the United States, finds a new report from QuintilesIMS. The characteristics of biopharmaceutical innovation have evolved in some respects over the past two decades. Most notably, ...
By PharmaVoice Team • Feb. 1, 2017 -
PharmaVoice Team/PharmaVoice
Innovator's Corner
Gene Therapy for Better Sight Kathy High, M.D., President and Chief Scientific Officer at Spark Therapeutics, talks about the company’s gene therapy for inherited retinal diseases. Thanks to a renewed focus on gene therapy, researchers are uncovering new ways to treat diseases where no therapies ...
By Kathy High • Feb. 1, 2017 -
PharmaVoice Team/PharmaVoice
HealthTech
Google Trains AI to Spot Diabetic Retinopathy Trendwatch: From eye sight to brain injuries, technology enables better care. A few years ago, Google technologies began working on ways to improve the diabetic retinopathy (DR) screening process, specifically by taking advantage of recent advances in...
By PharmaVoice Team • Feb. 1, 2017 -
PharmaVoice Team/PharmaVoice
The Next Generation of Cancer Immunotherapy
Researchers and drug developers are gaining a better understanding of the immune system and how to better target cancer; as a result, immuno-oncology continues to be a key area of anticancer drug development. Researchers over the last few years have found that the immune system has the capability...
By Denise Myshko • Feb. 1, 2017 -
PharmaVoice Team/PharmaVoice
Update on Zika Research
First identified in Uganda in 1947, the Zika virus over the past two years has rapidly spread through Asia, the South Pacific, Hawaii, South America, Central America, and the Caribbean. In 2016, active local mosquito-borne transmission began to occur in North America, specifically in Florida and ...
By Denise Myshko • Feb. 1, 2017 -
PharmaVoice Team/PharmaVoice
Rare Disease Day Turns Spotlight on Research
On the last day in February, hundreds of patients’ groups from around the world will hold a host of activities to raise awareness about rare diseases. The international 10th annual Rare Disease Day, which is coordinated by the European Organization for Rare Diseases (EURORDIS), seeks to help the ...
By Kim Ribbink • Feb. 1, 2017 -
PharmaVoice Team/PharmaVoice
SHOWCASE FEATURE: Outsourcing: The Outsourcing Big Picture
Outsourcing is now firmly entrenched in the pharma industry. While pharmaceutical companies have been outsourcing back-office activities for many years now, they are increasingly turning to external partners for research and development activities that traditionally were retained in-house. Today,...
By PharmaVoice Team • Feb. 1, 2017 -
PharmaVoice Team/PharmaVoice
3-D Outsourcing: The Key to Improved Product Launches
Put yourself in this situation: You are the director of operations at a growing biotech company. It is either your first product launch or your previous product launches have been slow, inefficient and costly. It is up to you to improve commercialization by streamlining processes and using limite...
By Steve Devrieze • Feb. 1, 2017 -
PharmaVoice Team/PharmaVoice
Speak Out
Maximizing Patient Recruitment in Rare Disease Research Creating a pharmaceutical develop- ment program for the treatment of a rare disease is challenging. From re-cruiting and retaining patients and investi- gators, through to regulatory uncertainties and limited understanding of the natural his...
By Jeffrey Zucker • Feb. 1, 2017 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
Welcome to 2017 From funding to policy changes, 2017 according to analysts will be marked by uncertainty and opportunity. As the industy, as well as the country, prepares for the Trump Administration, EY U.S. Analyst Arda Ural, Ph.D., details the impact the new president’s policies will have on d...
By Taren Grom • Jan. 1, 2017 -
PharmaVoice Team/PharmaVoice
Innovator's Corner
A New Way to Treat Severe Asthma Dr. Bing Yao, Respiratory, Inflammation & Autoimmunity Head at MedImmune, talks about the company’s efforts to develop a next-generation asthma therapy. Severe, uncontrolled asthma is a debilitating and potentially fatal form of the disease. Uncontrolled asthm...
By Dr. Bing Yao • Jan. 1, 2017 -
PharmaVoice Team/PharmaVoice
HealthTech
AI and mHealth Tech: Instruments to Better Healthcare Computers can be trained to be more accurate than pathologists in assessing slides of lung cancer tissues, according to a study by researchers at the Stanford University School of Medicine. The researchers found that a machine-learning approac...
By PharmaVoice Team • Jan. 1, 2017 -
PharmaVoice Team/PharmaVoice
Last Word
Rising Pharma Opportunities in China Rick Pauls, President and CEO of DiaMedica, talks about how the Chinese market is poised for growth. PV: Why do you think the Chinese market has potential for the pharmaceutical industry? Pauls: The westernization of China is leading to increases in many disea...
By Rick Pauls • Jan. 1, 2017 -
PharmaVoice Team/PharmaVoice
Venture Capital Funding
According to the MoneyTree Report from PwC, the life-sciences industry continues to be the second most invested destination after software, in terms of dollars. Life-Sciences’ VC Investment The life-sciences’ record-high investment spree of 2015 came to an end in Q4 with the lowest quarter of in...
By PharmaVoice Team • Jan. 1, 2017 -
PharmaVoice Team/PharmaVoice
Organs On Chips
One day, precision medicine will take into account the genes, environment, and lifestyle of each person. Through the use of an emerging technology that melds engineering, biology, and IT, researchers are able to see what hasn’t been possible before: the inner workings of human biology and disease...
By Denise Myshko • Jan. 1, 2017 -
PharmaVoice Team/PharmaVoice
Disease State: HIV Update
Since the beginning of the HIV epidemic, almost 70 million people worldwide have been infected with the virus that causes AIDS. It is estimated that 36.7 million people are currently living with HIV globally. Tremendous gains have been made in treating these patients, helping them to live longer,...
By Denise Myshko • Jan. 1, 2017 -
PharmaVoice Team/PharmaVoice
Focus on Rare Diseases
Rare diseases have been a focus of drug development for decades, and since the 1980s, there have been financial, legal, and legislative incentives, such as the Orphan Drug Act, that are drawing companies of all sizes to enter the market. Rafal Kokolus, senior engagement manager, inVentiv Health C...
By PharmaVoice Team • Jan. 1, 2017 -
PharmaVoice Team/PharmaVoice
Pharma Trax
CROs are Leading Drive to Improve the Efficiency of Clinical Trials Trending now: Survey reveals significant improvements in inspection readiness among CROs. A global industry survey by Veeva of trial master file (TMF) owners shows growing use of electronic trial master file (eTMF) solutions a...
By PharmaVoice Team • Nov. 21, 2016
Previous
